Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ajai Chari, Paul G. Richardson, Dorothy Romanus, Meletios A. Dimopoulos, Pieter Sonneveld, Evangelos Terpos, Roman Hajek, Aditya Raju, Antonio Palumbo, Lauren E. Cain, Marlo Blazer, Hui Huang, Eileen Farrelly & Sikander Ailawadhi. (2020) Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Review of Hematology 13:4, pages 421-433.
Read now
Read now
Alison Stopeck, Adam Brufsky, Lisa Kennedy, Sumi Bhatta, Debajyoti Bhowmik, Jacqueline Buchanan, Nicolas Despiegel & Guy Hechmati. (2020) Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics 23:1, pages 37-47.
Read now
Read now
Evangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, Marco Campioni, Debajyoti Bhowmik, Lisa Kennedy & Wolfgang Willenbacher. (2019) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of Medical Economics 22:8, pages 766-776.
Read now
Read now
Parameswaran Hari, Marlo Blazer, Aditya Raju, Eileen Farrelly, Richard Labotka, Tomas Skacel & Dorothy Romanus. (2019) Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA. Expert Review of Hematology 12:1, pages 71-79.
Read now
Read now
Debajyoti Bhowmik, Dionne M. Hines, Michele Intorcia & Rolin L. Wade. (2018) Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database. Journal of Medical Economics 21:6, pages 622-628.
Read now
Read now
Noopur Raje, Garson David Roodman, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Evangelos Terpos, Lisa Kennedy, Lorenzo Sabatelli, Michele Intorcia & Guy Hechmati. (2018) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Journal of Medical Economics 21:5, pages 525-536.
Read now
Read now
Articles from other publishers (14)
Larysa SanchezAjai ChariMu ChengDasha CherepanovMaral DerSarkissianFei HuangDawn Marie StullJonathan DaboraMelanie YoungStephen J. NogaSelina PiMelody ZhangAzeem BanatwalaMei Sheng DuhSikander Ailawadhi. (2023) Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. Journal of Managed Care & Specialty Pharmacy 29:11, pages 1205-1218.
Crossref
Crossref
Sikander Ailawadhi, Augustina Ogbonnaya, Sharanya Murty, Dasha Cherepanov, Bridgette Kanz Schroader, Dorothy Romanus, Eileen Farrelly & Ajai Chari. (2022) Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant. Cancer Medicine 12:3, pages 3145-3159.
Crossref
Crossref
Faith Davies, Robert Rifkin, Caitlin Costello, Gareth Morgan, Saad Usmani, Rafat Abonour, Antonio Palumbo, Dorothy Romanus, Roman Hajek, Evangelos Terpos, Dasha Cherepanov, Dawn Marie Stull, Hui Huang, Xavier Leleu, Jesus Berdeja, Hans C. Lee, Katja Weisel, Michael Thompson, Mario Boccadoro, Jeffrey Zonder, Gordon Cook, Noemi Puig, Jorge Vela-Ojeda, Eileen Farrelly, Aditya Raju, Marlo Blazer & Ajai Chari. (2021) Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology 100:9, pages 2325-2337.
Crossref
Crossref
Meera Mohan, Manoj Kumar, Rohan Samant, Rudy Van HemertJrJr, Erming Tian, Shivang Desai, Frits van Rhee, Sharmilan Thanendrarajan, Carolina Schinke, Larry J. Suva, Shobhit Sharma, Mohamed Milad, Samantha Kendrick & Maurizio Zangari. (2021) Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience. Bone 146, pages 115876.
Crossref
Crossref
Jifang Zhou, Karen Sweiss, Edith A. Nutescu, Jin Han, Pritesh R. Patel, Naomi Y. Ko, Todd A. Lee, Brian C.-H. Chiu & Gregory S. Calip. (2021) Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare. JCO Oncology Practice 17:3, pages e294-e312.
Crossref
Crossref
Suying Li, Haifeng Guo, Yi Peng, Tingting Gong, Alan Fu, Debajyoti Bhowmik, Rohini K. Hernandez, Katherine B. Carlson, Kimberly A. Lowe, Jitesh Rana & Shuling Li. (2021) Discharge status and post-discharge healthcare costs after skeletal-related event hospitalizations among medicare patients with bone metastatic solid tumors or multiple myeloma. Journal of Bone Oncology 26, pages 100328.
Crossref
Crossref
María-Victoria Mateos, Leah Fink, Niranchana Koneswaran, Michele Intorcia, Christina Giannopoulou, Daniela Niepel & Michele Cavo. (2020) Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. BMC Cancer 20:1.
Crossref
Crossref
Ian M. Lahart, Sarah K. Weller & Amy A. Kirkham. (2020) Rising to the challenge: designing, implementing and reporting exercise oncology trials in understudied populations. British Journal of Cancer 123:2, pages 173-175.
Crossref
Crossref
Sikander Ailawadhi, Rohan Medhekar, Nicole Princic, Robert Fowler, Oth Tran, Debajyoti Bhowmik & Sumeet Panjabi. (2019) Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events. Journal of Oncology Pharmacy Practice 26:5, pages 1070-1079.
Crossref
Crossref
Burak EREN, İlker GÜLEÇ, Feyza KARAGÖZ GÜZEY, Ece SAĞLAM, Azmi TUFAN, Murat KARACAN & Nuri Serdar BAŞ. (2020) Omurilik Basısı Nedeniyle Dekompresyon Uygulanan Multipl Miyelom Olgularının Değerlendirilmesi. OSMANGAZİ JOURNAL OF MEDICINE.
Crossref
Crossref
Ajai Chari, Dorothy Romanus, Antonio Palumbo, Marlo Blazer, Eileen Farrelly, Aditya Raju, Hui Huang & Paul Richardson. (2019) Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark RCTs in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Crossref
Christopher Kim, Sumita Bhatta, Lori Cyprien, Rafael Fonseca & Rohini K. Hernandez. (2019) Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data. Journal of Bone Oncology 14, pages 100215.
Crossref
Crossref
John Ashcroft, Ignacio Duran, Herbert Hoefeler, Vito Lorusso, Diana Lueftner, Marco Campioni, Michele Intorcia & Amit Bahl. (2018) Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study. European Journal of Haematology 100:5, pages 479-487.
Crossref
Crossref
Parameswaran Hari, Dorothy Romanus, Antonio Palumbo, Katarina Luptakova, Robert M. Rifkin, Linh Mai Tran, Aditya Raju, Eileen Farrelly, Stephen J. Noga, Marlo Blazer & Ajai Chari. (2018) Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Crossref